Search Videos and More

Showing 109 - 120 of 605 results

Previous| 1... 9 | 10 | 11 ...51 |Next


Kimberly Stegmaier named as Pediatric Oncology Chair at Dana-Farber News

Kimberly Stegmaier named as Pediatric Oncology Chair at Dana-Farber

Kimberly Stegmaier, MD, was named Chair of Pediatric Oncology at Dana-Farber Cancer Institute and Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital, in an announcement made today. Her appointment is effective April 1, 2025.
Dana-Farber Research News 02.15.2025 News

Dana-Farber Research News 02.15.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from January 16 through January 31.
Early Cancer Detection Studies for High-Risk People News

Early Cancer Detection Studies for High-Risk People

A blood test can now detect the presence of 50 different cancers — most of which do not have any other means of screening.
Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings News

Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings

Dana-Farber Cancer Institute researchers presented key research studies at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy.
Dana-Farber Researchers Present Findings at 2025 ASCO Genitourinary Cancers Symposium News

Dana-Farber Researchers Present Findings at 2025 ASCO Genitourinary Cancers Symposium

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium, on February 13-15, 2025, in San Francisco, Calif.
A Year of Advances in Genitourinary Cancer News

A Year of Advances in Genitourinary Cancer

Dana-Farber’s genitourinary cancer team is devoted to research that will advance patient care and improve patient’s lives. Recently, that research — all of it years in the making — has paid off with major achievements.
What is a Menin Inhibitor? News

What is a Menin Inhibitor?

Menin, a protein located in the nucleus of various human cell types, often functions as a tumor suppressor by inhibiting excessive cell growth and division.
Dana-Farber Research News 02.01.2025 News

Dana-Farber Research News 02.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from January 1 through January 15.
Can Metastatic Breast Cancer Be Cured? News

Can Metastatic Breast Cancer Be Cured?

When Yvonne Fantaci discovered she had breast cancer at age 60, it had already spread to her lungs, liver, and elsewhere. Fantaci felt blindsided. She was otherwise completely healthy. She never expected such a shocking diagnosis.
Expanding Options for Patients with Ovarian Cancer News

Expanding Options for Patients with Ovarian Cancer

In 2021, a novel drug called belzutifan was approved by the U.S. Food and Drug Administration (FDA) to treat clear cell renal cell carcinoma, a form of kidney cancer.
Blood Test Could Guide Use of Anti-Inflammatory Drug Celecoxib to Reduce Risk of Colon Cancer Recurrence News

Blood Test Could Guide Use of Anti-Inflammatory Drug Celecoxib to Reduce Risk of Colon Cancer Recurrence

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit from adding of celecoxib, to post surgery treatment.
Dana-Farber Investigators Pinpoint Keys to Cell Therapy Response for Leukemia News

Dana-Farber Investigators Pinpoint Keys to Cell Therapy Response for Leukemia

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission.

Showing 109 - 120 of 605 results

Previous| 1... 9 | 10 | 11 ...51 |Next